Wells Fargo analyst Derek Archila assigned a Hold rating on Kezar Life Sciences (KZR – Research Report) yesterday and set a price target ...

Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.

William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data ...

Kezar Life Sciences saw its share tumble more than 42% to 40.77 yesterday, after it revealed it was voluntarily pausing ...

According to the safety findings, four Grade Five serious adverse events were reported during the Phase II PALIZADE trial.

KEZAR Life Sciences said on Monday it has paused a trial of its experimental drug for lupus to review safety data after four patients died in the mid-stage study. The San Francisco-based company said ...

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. (BMS) in a research collaboration and license agreement totaling $3.61 billion. The two companies ...

Kezar Life Sciences said it voluntarily suspended enrollment and dosing in a clinical trial of a treatment for an autoimmune kidney disease after four patients died.

Lupus nephritis progression may be faster in patients with interstitial fibrosis/tubular atrophy (IFTA). Now a nomogram may predict it.

Kezar Life Sciences is suspending enrollment and dosing in a lupus trial after four patients died in the mid-stage study of ...

Kezar Life Sciences went all in on its autoimmune candidate zetomipzomib after a restructuring last year. | The voluntary ...

This summary provides key updates in the healthcare sector, including Kezar Life Sciences halting a lupus treatment trial, challenges in sickle cell gene therapy, Glenview Capital's improvements at ...